[Role of oxidative stress in diabetic vascular complications].
Inoguchi
Toyoshi
T
Department of Medicine and Bioregulatory Sicence, Postgraduate School of Medical Sciences, Kyushu University.
Takayanagi
Ryoichi
R
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000209:etiology*; D005947:Glucose / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006595:Hexosamines / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008928:Mitochondria / Q000378:metabolism; D019255:NADPH Oxidases / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology*; D011108:Polymers / Q000378:metabolism; D014969:Xanthine Oxidase / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D017127:Glycation End Products, Advanced; D006595:Hexosamines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011108:Polymers; C024617:polyol; D014969:Xanthine Oxidase; D019255:NADPH Oxidases; D005947:Glucose